Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024
Amicus Therapeutics (Nasdaq: FOLD) has announced its participation in three major investor conferences in November 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Amicus Therapeutics (Nasdaq: FOLD) has announced its participation in three major investor conferences in November 2024. The company will present at the Guggenheim Healthcare Innovation Conference in Boston on November 12 at 2:30 p.m. ET and the Jefferies London Healthcare Conference on November 19 at 8:00 a.m. GMT. Management will also attend the J.P. Morgan Equity Opportunities Forum on November 13.
Live audio webcasts of the presentations will be available through the investors section of the Amicus Therapeutics website. The company focuses on developing and delivering medicines for rare diseases, maintaining a strong commitment to patient care and advancing its pipeline of first- or best-in-class medicines.
Details
News Market Reaction – FOLD
The recorded move for FOLD in the trading session of this news was +0.44%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PRINCETON, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in November.
- Guggenheim Healthcare Innovation Conference in Boston, MA, on Tuesday, November 12, 2024, at 2:30 p.m. ET
- Jefferies London Healthcare Conference in London, U.K. on Tuesday, November 19, 2024, at 8:00 a.m. GMT
A live audio webcast of each presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations.
Additionally, management will attend the J.P. Morgan Equity Opportunities Forum on Wednesday, November 13, 2024.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on X and LinkedIn.
CONTACT:
Investors:
Amicus Therapeutics
Andrew Faughnan
Vice President, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809
Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Affairs and Communications
dmoore@amicusrx.com
(609) 662-5079
FOLD–G
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.